Compare MRNA & RCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | RCL |
|---|---|---|
| Founded | 2010 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2B | 81.6B |
| IPO Year | 2018 | 1997 |
| Metric | MRNA | RCL |
|---|---|---|
| Price | $199.18 | $303.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 29 |
| Target Price | $164.53 | ★ $357.70 |
| AVG Volume (30 Days) | ★ 11.4M | 1.8M |
| Earning Date | 11-06-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 1.87% |
| EPS Growth | 21.77 | ★ 42.69 |
| EPS | N/A | ★ 14.12 |
| Revenue | ★ $19,263,000,000.00 | $8,777,845,000.00 |
| Revenue This Year | $24.09 | $9.04 |
| Revenue Next Year | $11.33 | $7.32 |
| P/E Ratio | ★ N/A | $22.47 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $222.22 |
| 52 Week High | $280.80 | $356.39 |
| Indicator | MRNA | RCL |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 49.24 |
| Support Level | $181.02 | $264.56 |
| Resistance Level | $254.48 | $336.57 |
| Average True Range (ATR) | 17.92 | 11.52 |
| MACD | -7.14 | -3.17 |
| Stochastic Oscillator | 11.39 | 1.48 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Royal Caribbean is the world's second-largest cruise company by revenues, operating 71 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021, plans to launch its new Celebrity River Cruise brand in 2027, and is set to operate eight private destination locations by 2028.